Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET

Company Participants

Brennan Doyle - Head of Investor Relations
Jeffrey Dayno - President & Chief Executive Officer
Jeffrey Dierks - Chief Commercial Officer
Kumar Budur - Chief Medical Officer & Scientific Officer
Sandip Kapadia - Chief Financial Officer & Chief Administrative Officer

Conference Call Participants

Graig Suvannavejh - Mizuho
Ami Fadia - Needham
Charles Duncan - Cantor Fitzgerald
David Amsellem - Piper Sandler
Danielle Brill - Raymond James
Ash Verma - UBS
Corinne Johnson - Goldman Sachs
Jason Gerberry - Bank of America
Francois Brisebois - Oppenheimer

Operator

Good morning. My name is Todd, and I will be your conference operator today. At this time, I would like to welcome everyone to Harmony Biosciences Third Quarter 2024 Financial Results Conference Call. All participants have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session [Operator Instructions] Please be advised that today's conference may be recorded. [Operator Instructions]

I will now turn the call over to Brennan Doyle, Head of Investor Relations. Please go ahead.

Brennan Doyle

Thank you, operator. Good morning, everyone, and thank you for joining us today as we review Harmony Biosciences third quarter 2024 financial results and provide a business update. Before we start, I encourage everyone to go to the Investors section of our website to find the materials that accompany our discussion today, including a reconciliation of our GAAP to non-GAAP financial measures. At this stage of our life cycle, we believe non-GAAP financial results better represent the underlying business performance.

Our speakers on today's call are Dr. Jeffrey Dayno, President and CEO; Jeffrey Dierks, Chief Commercial Officer; Dr. Kumar Budur, Chief Medical and Scientific Officer; and Sandip Kapadia, Chief Financial Officer and Chief Administrative Officer.

As a reminder, we will be making forward-looking statements today, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties. Our actual results may differ materially, and we undertake no obligation to update these statements even if circumstances change. We encourage you to consult the risk factors referenced in our SEC filings for additional details.

I would now like to turn the call over to Dr. Jeffrey Dayno. Jeff?

Jeffrey Dayno

Thank you, Brennan, and thanks, everyone, for joining our conference call today. Q3 was another quarter of strong momentum for the team at Harmony, driving significant revenue growth for WAKIX and advancing our late-stage clinical development programs. At our successful Investor Day event earlier this month, we were excited to share new data and outlined a clear path toward becoming the leading CNS company focused on developing and delivering innovative treatments to patients with unmet medical needs.